

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.
This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance:	Policy #:	Group #:

Is the requested medication New or Continuation of Therapy? If continuation, list start date: _____
 Is this patient currently hospitalized? Yes No If recently discharged, list discharge date: _____

Section B - Physician Information

First Name:	Last Name:	M.D./D.O.
Address:		City: State: ZIP code:
Phone:	Fax:	NPI #: Specialty:
Office Contact Name / Fax attention to:		

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:
Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____	

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs
Please refer to www.uhccommunityplan.com for a list of preferred alternatives

Member First name:	Member Last name:	Member DOB:
--------------------	-------------------	-------------

Clinical and Drug Specific Information

All Requests:

- **What is the patient's diagnosis? (check which applies)**
 - Central Nervous System (CNS) Cancer Non-Small Cell Lung Cancer (NSCLC)

- **Is the disease recurrent or metastatic? Yes No (check which applies)**
 - Recurrent Metastatic

Requests for Central Nervous System Cancer:

- **Is the primary disease (tumor) responsive to Tagrisso therapy (e.g., EGFR T790M mutation-positive NSCLC)?**
 - Yes No

Requests for Non-Small Cell Lung Cancer:

- **Is the patient's disease: (check which applies)**
 - Sensitizing epidermal growth factor receptor (EGFR) mutation-positive
 - EGFR T790M mutation-positive
 - None of the above

- **Will Tagrisso be used as first-line therapy or subsequent therapy after disease progression while on Tagrisso therapy? Yes No**

- **Does the patient have a history of failure, contraindication, or intolerance to prior EGFR tyrosine kinase inhibitor (TKI) therapy [e.g., Tarceva (erlotinib), Gilotrif (afatinib), Iressa (gefitinib)]? Yes No** (If yes, complete Section D above with medication information, including dose, duration, date of trial, and reason for discontinuation)

Requests for Continuation of Therapy:

- **Does the patient have a documented positive clinical response to Tagrisso therapy? Yes No**
 If yes, list response: _____

- **Does the patient show evidence of progressive disease while on Tagrisso therapy? Yes No**

Physician Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.

Website: uhcommunityplan.com